PCNA and neoplasm: Interestingly, a significant increase in the percentage of CC3-positive tumour cells was observed following olaparib treatment, which was accompanied by a significant decrease in the percentage of PCNA-positive tumour cells (Figure 7A–C), suggesting the CU-PC01 PDX model is sensitive to PARP inhibition ex vivo.